[go: up one dir, main page]

ATE210134T1 - Heterocyclisch substituierte imidazolidine, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen - Google Patents

Heterocyclisch substituierte imidazolidine, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen

Info

Publication number
ATE210134T1
ATE210134T1 AT95402174T AT95402174T ATE210134T1 AT E210134 T1 ATE210134 T1 AT E210134T1 AT 95402174 T AT95402174 T AT 95402174T AT 95402174 T AT95402174 T AT 95402174T AT E210134 T1 ATE210134 T1 AT E210134T1
Authority
AT
Austria
Prior art keywords
opt
substd
products
production
pharmaceutical preparations
Prior art date
Application number
AT95402174T
Other languages
English (en)
Inventor
Andre Claussner
Francois Goubet
Jean-Georges Teutsch
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE210134T1 publication Critical patent/ATE210134T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT95402174T 1994-09-29 1995-09-28 Heterocyclisch substituierte imidazolidine, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen ATE210134T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9411649A FR2725206B1 (fr) 1994-09-29 1994-09-29 Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
ATE210134T1 true ATE210134T1 (de) 2001-12-15

Family

ID=9467411

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95402174T ATE210134T1 (de) 1994-09-29 1995-09-28 Heterocyclisch substituierte imidazolidine, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen

Country Status (19)

Country Link
US (3) US5646172A (de)
EP (1) EP0704448B1 (de)
JP (1) JPH0899977A (de)
CN (1) CN1055471C (de)
AT (1) ATE210134T1 (de)
AU (1) AU707569B2 (de)
BR (1) BR9504205A (de)
CA (1) CA2159425A1 (de)
DE (1) DE69524344T2 (de)
DK (1) DK0704448T3 (de)
ES (1) ES2169112T3 (de)
FI (1) FI111259B (de)
FR (1) FR2725206B1 (de)
HU (1) HU222564B1 (de)
IL (1) IL114939A (de)
PT (1) PT704448E (de)
RU (1) RU2170231C2 (de)
UA (1) UA48937C2 (de)
ZA (1) ZA957568B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741342B1 (fr) * 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
FR2742749B1 (fr) * 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
DE19632126A1 (de) * 1996-08-09 1998-02-12 Bayer Ag Phenylsubstituierte cyclische Ketoenole
US20020142993A1 (en) * 2000-10-12 2002-10-03 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of bicyclic compounds
WO2005023810A1 (en) * 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
AU2004305075A1 (en) * 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
NZ550102A (en) * 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
NZ710355A (en) 2005-05-13 2017-01-27 Univ California Diarylhydantoin compounds
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2007011810A1 (en) * 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP2656842B1 (de) 2006-03-27 2016-08-10 The Regents of The University of California Androgenrezeptor-modulator zur behandlung von prostatakrebs und androgenrezeptor-assoziierte erkrankungen
CN102755318B (zh) 2006-03-29 2014-09-10 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB0610765D0 (en) * 2006-05-31 2006-07-12 Proskelia Sas Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
WO2008030412A2 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009055053A2 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
CA2773038A1 (en) 2009-09-04 2011-03-10 P. Jeffrey Conn Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP2475647B1 (de) 2009-09-10 2015-11-04 Suzhou Kintor Pharmaceuticals, Inc. Androgenrezeptorantagonisten und verwendungen davon
BR112012020558B1 (pt) 2010-02-16 2020-11-03 Aragon Pharmaceuticals, Inc moduladores do receptor de androgênio, suas composições farmacêuticas, e seus usos
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
PL2683694T3 (pl) * 2011-03-10 2016-10-31 Antagoniści receptora androgenowego i ich zastosowania
EA037806B1 (ru) 2012-09-26 2021-05-24 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US10011874B2 (en) 2013-02-25 2018-07-03 Novartis Ag Androgen receptor mutation
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US20190209469A1 (en) 2016-08-20 2019-07-11 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
SG11202003402QA (en) 2017-10-16 2020-05-28 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS421179Y1 (de) * 1964-03-13 1967-01-24
JPS4623738Y1 (de) * 1968-05-29 1971-08-16
DE2126532A1 (de) * 1971-05-28 1972-12-07 Merck Patent Gmbh, 6100 Darmstadt Neue Derivate der 6-Aminopenicillansäure und Verfahren zu ihrer Herstellung
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
US4320135A (en) * 1980-05-19 1982-03-16 Sandoz, Inc. Inhibiting growth hormone secretion with 5,5-substituted hydantoin derivatives
EP0091596B1 (de) * 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
US5221675A (en) * 1989-12-15 1993-06-22 Abbott Laboratories Aza-spirocyclic compounds that enhance cholinergic neurotransmission
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
CN1127753A (zh) 1996-07-31
DE69524344D1 (de) 2002-01-17
CN1055471C (zh) 2000-08-16
AU707569B2 (en) 1999-07-15
ES2169112T3 (es) 2002-07-01
FR2725206B1 (fr) 1996-12-06
PT704448E (pt) 2002-05-31
HU222564B1 (hu) 2003-08-28
HU9502841D0 (en) 1995-11-28
EP0704448A1 (de) 1996-04-03
US5646172A (en) 1997-07-08
FI954612L (fi) 1996-03-30
UA48937C2 (uk) 2002-09-16
DE69524344T2 (de) 2002-08-22
JPH0899977A (ja) 1996-04-16
IL114939A0 (en) 1995-12-08
CA2159425A1 (fr) 1996-03-30
IL114939A (en) 2005-11-20
HUT72748A (en) 1996-05-28
ZA957568B (en) 1996-09-09
RU2170231C2 (ru) 2001-07-10
BR9504205A (pt) 1996-08-06
US5705654A (en) 1998-01-06
FR2725206A1 (fr) 1996-04-05
AU3292195A (en) 1996-04-18
FI111259B (fi) 2003-06-30
DK0704448T3 (da) 2002-03-25
FI954612A0 (fi) 1995-09-28
US5958936A (en) 1999-09-28
EP0704448B1 (de) 2001-12-05

Similar Documents

Publication Publication Date Title
ATE210134T1 (de) Heterocyclisch substituierte imidazolidine, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen
ATE128975T1 (de) Harnstoffderivate, verfahren zu ihrer herstellung und diese enthaltende medikamente.
DE3778800D1 (de) Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel.
DE69327438D1 (de) Therapeutische Mittel für die Parkinsonsche Krankheit
ATE141277T1 (de) Neue phosphonobernsteinsäurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
ATE302778T1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
IT1224416B (it) Chelanti macrociclici e loro chelati
DE58901510D1 (de) 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
ATE127807T1 (de) N-heteroaryl-purin-6-amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
EP0369263A3 (de) Präparate zur topischen Behandlung von Hautkrankheiten
ATE122042T1 (de) Pyrazoloisoquinoline-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
DE3882438D1 (de) Alkansulfonanilid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung.
HUP9801442A2 (hu) Fenil-ecetsav-származékok, eljárás és intermedierek előállításukhoz, valamint inszekticidként, akaricidként, nematocidként és fungicidként való alkalmazásuk
DK0637583T3 (da) 1-Aryloxy-3-alkylamino-2-propanol-nitratestere, anvendelse heraf og tilsvarende farmaceutisk præparat
ATE171704T1 (de) Optisch wirksame alkylendioxybenzolderivate und ihre verwendung als arzneimittel
ATE88460T1 (de) Verbindungen zur behandlung von harninkontinenz.
ATE238660T1 (de) Triazolyloxybenzyl-alkoxyacrylsäureester, verfahren zu ihrer herstellung und ihre verwendung
ATE123776T1 (de) Aminoalkylchromone, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
IE800900L (en) Pyrrolidinyl-benzoic acid derivatives.
DE68922605D1 (de) Verfahren zur Herstellung von (-)2-(2-(2-Aminoethoxy)ethoxy)methyl)-4-(2,3-dichlorphenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridin, und Zwischenprodukt zu dessen Herstellung.
ATE121724T1 (de) Neue salze der 2-(2,6-dichloranilino)- phenylessigsäure, verfahren zu ihrer herstellung und ihre verwendung für topisch anwendbare pharmazeutische zubereitungen.
PT87954A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de dioxopiperidina, com efeito antipsicotico
ATE119888T1 (de) 5-(amino)-triazolylcarbothioamidderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel sowie verwendung der ersteren.
DE69225381D1 (de) Nootrope Wirkstoffe
DE2963724D1 (en) Clavulanic acid derivatives, their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee